share_log

Short Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Drops By 35.6%

Short Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Drops By 35.6%

空頭股數在ProShares UltraShort納斯達克生物技術公司(納斯達克股票代碼:BIS)下跌35.6%
kopsource ·  2022/11/30 10:31

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Rating) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 32,500 shares, a decrease of 35.6% from the October 31st total of 50,500 shares. Based on an average trading volume of 15,800 shares, the days-to-cover ratio is currently 2.1 days.

ProShares UltraShort納斯達克生物科技公司(納斯達克:BIS-GET評級)在11月份看到空頭股數業務大幅下降。截至11月15日,空頭股數共有3.25萬股,比10月31日的5.05萬股減少了35.6%。以15,800股的平均成交量計算,目前天數與回補比率為2.1天。

ProShares UltraShort Nasdaq Biotechnology Price Performance

ProShares UltraShort納斯達克生物技術性價比

NASDAQ BIS traded up $0.09 on Wednesday, reaching $19.86. The company's stock had a trading volume of 7,848 shares, compared to its average volume of 24,243. ProShares UltraShort Nasdaq Biotechnology has a twelve month low of $18.82 and a twelve month high of $35.64. The firm's 50 day moving average is $22.35 and its two-hundred day moving average is $24.43.

週三,納斯達克國際股價上漲0.09美元,至19.86美元。該公司股票的總成交量為7848股,而其平均成交量為24243股。ProShares UltraShort納斯達克生物科技股的12個月低點為18.82美元,12個月高位為35.64美元。該公司的50日移動均線切入位為22.35美元,200日移動均線切入位為24.43美元。

Get
到達
ProShares UltraShort Nasdaq Biotechnology
ProShares超短波納斯達克生物技術
alerts:
警報:

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

機構投資者買入ProShares UltraShort納斯達克生物技術股

A number of institutional investors and hedge funds have recently bought and sold shares of BIS. UBS Group AG lifted its stake in ProShares UltraShort Nasdaq Biotechnology by 54.7% during the first quarter. UBS Group AG now owns 1,371 shares of the company's stock valued at $33,000 after buying an additional 485 shares in the last quarter. IMC Chicago LLC lifted its stake in ProShares UltraShort Nasdaq Biotechnology by 12.5% during the second quarter. IMC Chicago LLC now owns 21,003 shares of the company's stock valued at $566,000 after buying an additional 2,335 shares in the last quarter. Finally, Citadel Advisors LLC lifted its stake in ProShares UltraShort Nasdaq Biotechnology by 234.0% during the second quarter. Citadel Advisors LLC now owns 34,972 shares of the company's stock valued at $943,000 after buying an additional 24,501 shares in the last quarter.

一些機構投資者和對衝基金最近買賣了國際清算銀行的股票。今年第一季度,瑞銀集團(UBS Group AG)增持了ProShares UltraShort納斯達克生物技術公司的股份54.7%。瑞銀集團目前持有1,371股該公司股票,價值33,000美元,上一季度又購買了485股。IMC Chicago LLC在第二季度增持了ProShares UltraShort納斯達克生物科技公司的股份12.5%。IMC Chicago LLC現在持有該公司21,003股股票,價值56.6萬美元,上個季度又購買了2,335股。最後,Citadel Advisors LLC在第二季度將其在ProShares UltraShort納斯達克生物技術公司的持股比例提高了234.0%。Citadel Advisors LLC現在擁有34,972股該公司股票,價值943,000美元,上個季度又購買了24,501股。

About ProShares UltraShort Nasdaq Biotechnology

關於ProShares UltraShort納斯達克生物技術

(Get Rating)
(獲取評級)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.

ProShares超納斯達克生物科技(基金)只尋求一天的投資結果,不尋求較長時期的投資結果。基金尋求扣除費用和費用前的每日投資結果,相當於該指數每日業績的兩倍(200%)。超過一個交易日的基金回報將是這段時間內每一天的回報的複合結果,這很可能與同期納斯達克生物技術指數(該指數)的回報兩倍(200%)不同。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on ProShares UltraShort Nasdaq Biotechnology (BIS)
  • Dark Clouds Are Gathering For Cloud Stocks
  • 3 Dividend Growers With Good 2023 Growth Prospects
  • Hormel: Is This The Time To Buy?
  • Struggling Axsome Stock Could Bounce Back on Drug Trial Success
  • Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
  • 免費獲取StockNews.com關於ProShares UltraShort納斯達克生物技術的研究報告
  • 烏雲雲集,雲股雲集
  • 3個具有良好2023年增長前景的股息增長者
  • 霍梅爾:現在是買進的時候嗎?
  • 苦苦掙扎的Axome股票可能因藥物試驗成功而反彈
  • 哪些股票是黑色星期五,網絡星期一的贏家和輸家?

Receive News & Ratings for ProShares UltraShort Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

獲得ProShares UltraShort納斯達克生物科技日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProShares UltraShort納斯達克生物技術和相關公司的最新新聞和分析師評級的每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論